Texanes -: Anticancer drug with unique mechanism of action

被引:0
|
作者
Borek-Dohalská, L [1 ]
Stiborová, M [1 ]
机构
[1] Charles Univ, Fac Sci, Dept Biochem, Prague, Czech Republic
来源
CHEMICKE LISTY | 2000年 / 94卷 / 04期
关键词
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Taxnes (taxoids) are a new group of compounds with a significant anticancer activity. These compounds are mainly used for therapy of breast and ovarian cancer. Paditaxel and docetaxel, two representatives of these anticancer drugs, are natural products extracted from Taxus brevifolia and T. baccam L., respectively. Taxanes exhibit a unique mechanism of action. They prevent depolymerization of microtubules, important proteins in cell proliferation. Taxanes rank among the so-called mitotic poisons: docetaxel is mainly active in the S phase, while paclitaxel in the G(2)/M phase of the cell cycle. Metabolism of paclitaxel in humans is different from that in experimental animals. Major human metabolite of paclitaxel is 6 alpha-hydroxypaclitaxel. Formation of this metabolite is catalyzed by CYP2C8, while the CYP3A subfamily mediates formation of minor metabolites of paclitaxel. Docetaxel is metabolized in humans and rats in the same way; therefore, rats are a suitable model for studies of docetaxel metabolism in humans. The major metabolite is hydroxydocetaxel. CYP3As were identified as the enzymes participating in metabolism of docetaxel in both species. The review summarizes data concerning the mechanism of action of taxanes and their metabolism. Additional information on metabolic transformalion of these anticancer drugs may serve for potential improvement of their chemotherapeutic efficiencies.
引用
收藏
页码:226 / 229
页数:4
相关论文
共 50 条
  • [1] SURAMIN - AN ANTICANCER DRUG WITH A UNIQUE MECHANISM OF ACTION
    STEIN, CA
    LAROCCA, RV
    THOMAS, R
    MCATEE, N
    MYERS, CE
    JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (04) : 499 - 508
  • [2] Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action
    Aune, GJ
    Furuta, T
    Pommier, Y
    ANTI-CANCER DRUGS, 2002, 13 (06) : 545 - 555
  • [3] OMEPRAZOLE, A NEW ANTIULCER DRUG WITH A UNIQUE MECHANISM OF ACTION
    LINDBERG, P
    BRANDSTROM, A
    WALLMARK, B
    ACTA PHARMACEUTICA SUECICA, 1987, 24 (06): : 329 - 332
  • [4] Ferrocenes as new anticancer drug candidates: Determination of the mechanism of action
    Skoupilova, Hana
    Bartosik, Martin
    Sommerova, Lucia
    Pinkas, Jiri
    Vaculovic, Tomas
    Kanicky, Viktor
    Karban, Jindrich
    Hrstka, Roman
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 867
  • [5] New anticancer agent with minimal side effects has unique mechanism of action
    Hanauske, A
    ONCOLOGY-NEW YORK, 2000, 14 (02): : 164 - 164
  • [6] Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis
    Phetsuksiri, B
    Jackson, M
    Scherman, H
    McNeil, M
    Besra, GS
    Baulard, AR
    Slayden, RA
    DeBarber, AE
    Barry, CE
    Baird, MS
    Crick, DC
    Brennan, PJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (52) : 53123 - 53130
  • [7] Towards the elucidation of the mechanism of action of an inert ruthenium anticancer drug candidate
    Gasser, Gilles
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [8] Nucleoside-based anticancer drugs: Mechanism of action and drug resistance
    Hruba, Lenka
    Das, Viswanath
    Hajduch, Marian
    Dzubak, Petr
    BIOCHEMICAL PHARMACOLOGY, 2023, 215
  • [9] HPMA copolymer-anticancer drug conjugates:: design, activity, and mechanism of action
    Kopecek, J
    Kopecková, P
    Minko, T
    Lu, ZR
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) : 61 - 81
  • [10] Polymer-Drug Conjugates for Combination Anticancer Therapy: Investigating the Mechanism of Action
    Pasut, Gianfranco
    Greco, Francesca
    Mero, Anna
    Mendichi, Raniero
    Fante, Cristina
    Green, Rebecca J.
    Veronese, Francesco M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (20) : 6499 - 6502